Mirum Pharmaceuticals 2025 sales rise
Overview
Rare disease company reported 2025 net product sales of $521 mln, up from 2024
Company expects 2026 global net product sales of $630 mln to $650 mln
Company completed acquisition of Bluejay Therapeutics, adding brelovitug for HDV
Outlook
Mirum expects 2026 global net product sales of $630 mln to $650 mln
Volixibat VISTAS study topline data expected in Q2 2026
LIVMARLI EXPAND study topline data expected in Q4 2026
Result Drivers
LIVMARLI SALES GROWTH - LIVMARLI net product sales increased 69% year-over-year in the U.S., contributing significantly to 2025 revenue growth
GLOBAL EXPANSION - Expanded commercial access to 33 countries, enhancing global sales reach
BLUEJAY ACQUISITION - Acquisition of Bluejay Therapeutics added brelovitug for HDV, enhancing pipeline
Company press release: ID:nBwc886mla
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Product Sales |
| $148.93 mln |
|
Q4 Net Income |
| -$5.73 mln |
|
Q4 Operating Expenses |
| $153.50 mln |
|
Q4 Operating Income |
| -$4.57 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $112.50, about 4.7% above its February 24 closing price of $107.48
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Circle Stock Price Outlook: Will Circle Internet Group Rebound in 2026?
TradingKey - Circle Internet Group (CRCL) saw its stock price experience a roller coaster ride since its 2025 IPO debut at $31 a share. Those early fireworks faded, and the shares now sit roughly 75% below their June peak, though they’re still more than double the IPO level. Outside of that first-mo
Paramount Offers High Price Again to Bid for Warner Bros., Netflix Acquisition Hits Twists and Turns.
TradingKey - Hollywood media group Warner Bros. (WBD) announced Tuesday that it has received a revised acquisition proposal from Paramount (PSKY), raising the offer from the previous $30 to $31 per share in cash. The Board of Directors stated that this new bid "is likely to constitute a superior proposal" to the current agreement with Netflix and noted that negotiations between the two parties are continuing. The existing deal with Netflix (NFLX) remains in effect, as the Warner Bros. Board has not yet formally designated the Paramount offer as the superior proposal.
Nvidia Q4 Earnings: Market Fears Competition, but NVDA Moat is Beyond CUDA
All eyes are on Nvidia this week, as the company reports its 2026Q4 earnings.
Nvidia Q4 Earnings Preview: AI-Driven Growth Versus Market Expectations
TradingKey - NVIDIA (NVDA) is set to release its fourth quarter fiscal year 2026 earnings report after the market close on February 25, ET. As the world undergoes a period of rapid AI technological advancement, market debates over a capital expenditure bubble have intensified. In this context, NVIDIA’s results serve not only as a test of its business performance but also as a core bellwether for the sustainability of the global AI boom.
